New York Blood Center Enterprises’ (NYBCe) Lindsley F. Kimball Research Institute (LFKRI) today announced a scientific ...

This review explains how glucose scarcity, lipid disruption, amino acid deprivation, and toxic metabolites weaken CAR-T cells ...

In 2021, a woman with severe lupus at University Hospital Erlangen in Germany became the first person to receive CAR-T cell ...

There has been a swing towards in vivo CAR-T therapies lately, as big pharmas sign acquisition deals and new therapies hit ...

Scientists from Trinity College Dublin and RCSI University of Medicine and Health Sciences have created new "hybrid" immune ...

Once in a blue moon, an animal cloning story appears in the headlines before disappearing back into the ether. Cloning is one ...

Proxygen’s second lead candidate, CDK12, is a brain-penetrant glue degrader program designed to inactivate the transcriptional kinase CDK12, a target implicated in aggressive HER2-driven cancers and ...

AT-108 induces powerful, personalized anti-cancer responses by forcing tumor cells to present their antigens to the immune ...

How are bacterial pathogens able to effectively overcome plants' defense mechanisms? Researchers working with Professor Şuayb ...

Rejuvenation is one of the newest and most promising developments in longevity research, a field that began in earnest in ...

Cancer cells can disarm the immune system not just by hiding from it, but by actively reprogramming nearby immune cells into a suppressed state. This previously unrecognized molecular interaction, ...

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer—and identified a promising strategy to overcome that resistance.